Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection : A Randomized Clinical Trial
Importance: There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug.
Objective: To evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19.
Design, Setting, and Participants: This parallel, double-masked, randomized, phase IIb clinical trial with 81 adult patients who were hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon.
Interventions: Patients were allocated to receive high-dosage CQ (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days).
Main Outcomes and Measures: Primary outcome was reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group. Data presented here refer primarily to safety and lethality outcomes during treatment on day 13. Secondary end points included participant clinical status, laboratory examinations, and electrocardiogram results. Outcomes will be presented to day 28. Viral respiratory secretion RNA detection was performed on days 0 and 4.
Results: Out of a predefined sample size of 440 patients, 81 were enrolled (41 [50.6%] to high-dosage group and 40 [49.4%] to low-dosage group). Enrolled patients had a mean (SD) age of 51.1 (13.9) years, and most (60 [75.3%]) were men. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group. Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%).
Conclusions and Relevance: The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19.
Trial Registration: ClinicalTrials.gov Identifier: NCT04323527.
| Errataetall: |
CommentIn: JAMA Netw Open. 2020 Apr 24;3(4):e209035. - PMID 32330276 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
JAMA network open - 3(2020), 4 vom: 24. Apr., Seite e208857 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2020 Date Revised 18.12.2020 published: Electronic ClinicalTrials.gov: NCT04323527 CommentIn: JAMA Netw Open. 2020 Apr 24;3(4):e209035. - PMID 32330276 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamanetworkopen.2020.8857 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30914597X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30914597X | ||
| 003 | DE-627 | ||
| 005 | 20231225133252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamanetworkopen.2020.8857 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM30914597X | ||
| 035 | |a (NLM)32330277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borba, Mayla Gabriela Silva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection |b A Randomized Clinical Trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04323527 | ||
| 500 | |a CommentIn: JAMA Netw Open. 2020 Apr 24;3(4):e209035. - PMID 32330276 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug | ||
| 520 | |a Objective: To evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19 | ||
| 520 | |a Design, Setting, and Participants: This parallel, double-masked, randomized, phase IIb clinical trial with 81 adult patients who were hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon | ||
| 520 | |a Interventions: Patients were allocated to receive high-dosage CQ (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days) | ||
| 520 | |a Main Outcomes and Measures: Primary outcome was reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group. Data presented here refer primarily to safety and lethality outcomes during treatment on day 13. Secondary end points included participant clinical status, laboratory examinations, and electrocardiogram results. Outcomes will be presented to day 28. Viral respiratory secretion RNA detection was performed on days 0 and 4 | ||
| 520 | |a Results: Out of a predefined sample size of 440 patients, 81 were enrolled (41 [50.6%] to high-dosage group and 40 [49.4%] to low-dosage group). Enrolled patients had a mean (SD) age of 51.1 (13.9) years, and most (60 [75.3%]) were men. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group. Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%) | ||
| 520 | |a Conclusions and Relevance: The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19 | ||
| 520 | |a Trial Registration: ClinicalTrials.gov Identifier: NCT04323527 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Oseltamivir |2 NLM | |
| 650 | 7 | |a 20O93L6F9H |2 NLM | |
| 650 | 7 | |a chloroquine diphosphate |2 NLM | |
| 650 | 7 | |a 6E17K3343P |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 700 | 1 | |a Val, Fernando Fonseca Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Sampaio, Vanderson Souza |e verfasserin |4 aut | |
| 700 | 1 | |a Alexandre, Marcia Almeida Araújo |e verfasserin |4 aut | |
| 700 | 1 | |a Melo, Gisely Cardoso |e verfasserin |4 aut | |
| 700 | 1 | |a Brito, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Mourão, Maria Paula Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Brito-Sousa, José Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Baía-da-Silva, Djane |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Marcus Vinitius Farias |e verfasserin |4 aut | |
| 700 | 1 | |a Hajjar, Ludhmila Abrahão |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Rosemary Costa |e verfasserin |4 aut | |
| 700 | 1 | |a Balieiro, Antonio Alcirley Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Pacheco, Antônio Guilherme Fonseca |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, James Dean Oliveira |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Naveca, Felipe Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Xavier, Mariana Simão |e verfasserin |4 aut | |
| 700 | 1 | |a Siqueira, André Machado |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarzbold, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Croda, Júlio |e verfasserin |4 aut | |
| 700 | 1 | |a Nogueira, Maurício Lacerda |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Gustavo Adolfo Sierra |e verfasserin |4 aut | |
| 700 | 1 | |a Bassat, Quique |e verfasserin |4 aut | |
| 700 | 1 | |a Fontes, Cor Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Albuquerque, Bernardino Cláudio |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel-Ribeiro, Cláudio-Tadeu |e verfasserin |4 aut | |
| 700 | 1 | |a Monteiro, Wuelton Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Lacerda, Marcus Vinícius Guimarães |e verfasserin |4 aut | |
| 700 | 0 | |a CloroCovid-19 Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA network open |d 2018 |g 3(2020), 4 vom: 24. Apr., Seite e208857 |w (DE-627)NLM289300517 |x 2574-3805 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2020 |g number:4 |g day:24 |g month:04 |g pages:e208857 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamanetworkopen.2020.8857 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2020 |e 4 |b 24 |c 04 |h e208857 | ||